| Test | Method | Limit | Result |
|---|---|---|---|
| Purity | HPLC | ≥ 99.0% | 99.64% |
| Identity | Mass spectrometry | 3367.9 ± 1.0 Da | 3368.1 Da |
| Net content | Quantitative HPLC | ≥ 5 mg | 5.10 mg |
| Endotoxin | LAL assay | ≤ 0.5 EU/mg | 0.11 EU/mg |
| Sterility | Membrane filtration | No growth | No growth |
| Heavy metals | ICP-MS | ≤ 10 ppm total | 1.0 ppm |
| Moisture | Karl Fischer | ≤ 8.0% | 2.4% |
Modified GRF(1-29), no DAC
C152H252N44O42
3367.9 Da · 29 residues
29-residue chain. The full sequence and its mass-spec confirmation are on each lot certificate.
Endocrine · Modified GRF(1-29), no DAC
5 mg · 29 residues · 3367.9 Da
Size$9.00/mg
Quantity10+ of one compound: 40% off
Same-day dispatch on orders by 2 PM ET, Monday to Friday
Arrives in 2 business days, tracked
Free shipping over $150
Earn Research Credit on top of your discount. VIP earns 3x more.
For in-vitro research use only. Not for human or animal use.
Endocrine
Tesamorelin 10 mgEndocrine
CJC / IPA Blend 10 mgEndocrine
TESA / IPA Blend 15 mgEndocrine
Sermorelin 10 mgEndocrine
Ipamorelin 10 mgEndocrine
IGF-1 LR3 1 mgEndocrine
CJC-1295 DAC 5 mgEndocrine
Kisspeptin 10 mgTissue + immune
BPC-157 10 mgTissue + immune
TB-500 10 mgCopper peptides
GHK-Cu 50 mgNeural
Semax 10 mg01Verified test results
CJC-1295 lot SA-CJC-2610 was tested Oct 8, 2026 at an independent laboratory before it shipped. Every value is printed against its limit, so a pass means something.
Certificate of analysis
99.64%
Purity by HPLC
Profile drawn from the reported purity
Purity by HPLC, identity by mass spectrometry, net content by quantitative HPLC, endotoxin by LAL, sterility by membrane filtration, heavy metals by ICP-MS and moisture by Karl Fischer. Report SA-CJC-2610-01, Oct 8, 2026. Open the lot record.
Open any lot's certificate. Your order ships from the current released lot, and its QR code opens this record.
99.64%
HPLC purity
Tested Oct 8, 2026 · 7/7 assays · sample
99.11%
HPLC purity
Tested Sep 10, 2026 · 7/7 assays · sample
02Verify your vial
Every vial label carries a QR code. Point your phone camera at it.
The code opens that lot's certificate with every assay value. No phone? Type the lot from your packing slip on Verify a lot.
Each signed certificate links to the lab's own verification page, so the report can be confirmed independently of us.
03Analytical identity
Studied in growth-hormone-releasing-hormone receptor models in vitro.
| Compound | Modified GRF(1-29), no DAC |
|---|---|
| Formula | C152H252N44O42 |
| Molecular weight | 3367.9 Da |
| Residues | 29 |
| CAS | 863288-34-0 |
| Form | Lyophilised powder, 5 mg |
| Storage | Sealed at -20 °C, away from light and moisture |
Sequence
29-residue chain. The full sequence and its mass-spec confirmation are on each lot certificate.
Every heavy atom is placed from the sequence with ideal bond lengths and angles, so the connectivity is exact. The pose is idealised (an ideal helix) and is not a measured conformation. Identity for each lot is confirmed on its certificate.
Structure viewer04In the lab
CJC-1295 without DAC is a tetrasubstituted GRF(1-29); lab papers on this exact form are scarce, so those cited studied GRF(1-29) analogs. Such analogs act on the pituitary GRF receptor and adenylate cyclase, and D-residues at the cleavage site block DPP IV.
Compound
CJC-1295Modified GRF(1-29), no DAC; papers: GRF(1-29) analogsPituitary membranes
Endpoint studied
In 30 GRF(1-29) analogs, the C-terminal part set receptor recognition, the N-terminal part cyclase activation.
Robberecht 1986 · PMID 3018703Pituitary cells
Endpoint studied
[Ala15]GRH(1-29) was 5x as potent as [Gly15]; D-Ala2, Ala8 and Ala15 together gave a 27-fold gain.
Coy 1991 · PMID 1806385Human placental DPP IV
Endpoint studied
DPP IV cut GRF(1-29) at Ala2-Asp3; analogs with a D-residue at the cleavage site were not cleaved.
Bongers 1992 · PMID 1353684Pathways as reported in the cited laboratory studies. For in-vitro research use only.
05Research history
4 milestones, each linked to its PubMed record
Biochemical and Biophysical Research Communications
[D-Ala2]-GRF(1-29)-NH2 releases GH about 50 times more potently than the parent peptide in laboratory models.
PubMed · PMID 6231028Peptides
Thirty GRF(1-29) analogs are tested on pituitary GRF receptors and adenylate cyclase in membrane preparations.
PubMed · PMID 3018703European Journal of Pharmacology
Helix-favoring Ala8 and Ala15 substitutions, with D-Ala2, raise GH release potency in pituitary cells additively.
PubMed · PMID 1806385Biochimica et Biophysica Acta
Purified DPP IV cuts GRF(1-29) at Ala2-Asp3, while analogs with D-residues at the cleavage site resist it.
PubMed · PMID 1353684 LatestLaboratory research only, cited for research context. Not a claim about use in people.
06Questions
About CJC-1295, its certificate and your order.
Email [email protected], Monday to Friday. A person replies within one business day.
The current released lot, SA-CJC-2610. Scan the QR code on the vial label to open its certificate. The lot number is also on your packing slip, and the full certificate is here.
Every certificate is issued by an independent laboratory. Each lot has its own public record page with every assay value, and a link to verify the report on the lab's own site once the signed PDF is posted.
Vials are filled slightly over the labelled mass so that every vial meets it. Net content is measured on each lot and published as a number, not a pass.
Email [email protected] within 7 days with your order number and a photo and we will replace it.
Orders by 2 PM ET on a weekday ship the same day, with tracking emailed when the label prints.
No. It is sold strictly for in-vitro laboratory research and is not for human or animal use of any kind.
07Complete the box
3+ vials 25% off and 5+ vials 30% off across any mix, 10+ of one compound 40% off, 50+ of one compound 50% off.
Researcher verification
Smart Amino supplies compounds for in-vitro laboratory research. Before you enter, please confirm three things.
Your confirmation is remembered on this device
